Analyst Says He's Buying Merck (MRK) as 'Market Turns Towards Quality'

We recently published 10 Trending Stocks This Week. Merck & Co., Inc. (NYSE:MRK) is one of the trending stocks this week.

Joseph Terranova, Senior Managing Director, Virtus Investment Partners, said in a recent program on CNBC that he recently bought Merck & Co Inc (NYSE:MRK).

“I think at some point the market turns towards quality. When you look at factors, this year has been about momentum. I think it’s going to turn to quality. I think that’s going to take the market directly towards healthcare, so I am looking to build exposure. I did that by buying Merck & Co Inc (NYSE:MRK).”

Impax US Sustainable Economy Fund stated the following regarding Merck & Co., Inc. (NYSE:MRK) in its second quarter 2025 investor letter:

“Merck & Co., Inc. (NYSE:MRK) (Health Care, Pharmaceuticals) has a high Corporate Resilience score, and is contributing to a more robust and sustainable health care system through its leading drug and vaccine discovery. The stock’s weakness in Q2 was driven by a combination of concerns about its drug pipeline, particularly the competition from generic versions of Keytruda, and weaker market sentiment around Health Care stocks.”

While we acknowledge the potential of MRK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.